https://www.prnewswire.com/news-releases/acurx-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302024975.html
https://www.acurxpharma.com/news-media/press-releases
https://www.prnewswire.com/news-releases/acurx-announces-positive-phase-2b-results-showing-100-of-patients-who-had-clinical-cure-with-ibezapolstat-also-had-sustained-clinical-cure-302010978.html
https://www.acurxpharma.com/news-media/press-releases/detail/67/acurx-pharmaceuticals-inc-reports-third-quarter-2023
https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-reports-third-quarter-2023-results-and-provides-business-update-301985362.html
https://www.acurxpharma.com/news-media/press-releases/detail/66/acurx-announces-positive-top-line-ibezapolstat-phase-2
https://www.prnewswire.com/news-releases/acurx-announces-positive-top-line-ibezapolstat-phase-2-efficacy-results-with-96-clinical-cure-rate-in-patients-with-c-difficile-infection-301975406.html
https://www.acurxpharma.com/pipeline/publications
https://www.acurxpharma.com/news-media/press-releases/detail/65/acurx-pharmaceuticals-to-discuss-third-quarter-2023
https://www.prnewswire.com/news-releases/acurx-announces-ibezapolstat-scientific-posters-and-presentations-at-clostpath-2023-and-idweek-2023-scientific-conferences-301961565.html
https://www.biomicamed.com/wp-content/uploads/2021/01/Biomica_Presentation_MicrobiomeMovement2021.pdf
https://www.prnewswire.com/news-releases/global-microbiome-therapeutics-markets-2021-2032-need-for-current-good-manufacturing-practice-cgmp-certified-contract-manufacturing-facilities-301596050.html
https://www.prnewswire.com/news-releases/global-human-microbiome-markets-2019-2030-drugs-companies-therapeutics-diagnostics-case-studies-executive-insights-and-more-300980799.html
https://www.prnewswire.com/news-releases/human-microbiome-therapeutics-market-size-to-grow-by-usd-732-95-million-from-2022-to-2027--north-america-to-account-for-41-of-market-growth---technavio-302027860.html
https://www.prnewswire.com/news-releases/human-microbiome-therapeutics-market-size-to-grow-at-a-cagr-of-30-11-from-2022-to-2027--increase-in-industry-academia-collaboration-for-the-development-of-novel-therapeutics-is-a-major-trend--technavio-301890688.html
https://www.prnewswire.com/news-releases/global-precision-medicine-partnering-terms-and-agreements-2016-2023-unprecedented-access-to-the-deals-and-agreements-entered-into-by-the-worlds-leading-healthcare-companies-301820760.html
https://www.rebiotix.com/
https://microbiotica.com/microbiotica-announces-clinical-trial-collaboration-with-msd-to-evaluate-mb097-in-combination-with-keytruda-pembrolizumab-in-a-phase-1b-clinical-trial-in-melanoma/
https://microbiotica.com/media-centre/news/
https://www.prnewswire.com/news-releases/global-microbiome-therapeutics-market-report-2022-featuring-4d-pharma-enterome-finch-therapeutics-vedanta-bioscience--more-301692404.html
https://microbiotica.com/microbiotica-announces-transition-of-leadership/
https://www.prnewswire.com/news-releases/microbiome-therapeutics-global-market-to-reach-1-billion-by-2026-at-a-26-4-cagr-301650628.html
https://microbiotica.com/immuno-series-uk/
https://www.prnewswire.com/Sitemap_Index_Feb_2022.xml.gz
https://www.prnewswire.com/news-releases/ascentage-pharma-and-clover-biopharmaceuticals-announce-clinical-collaboration-to-evaluate-iap-antagonist-apg-1387-plus-the-recombinant-human-trail-trimer-fusion-protein-scb-313-for-the-treatment-of-peritoneal-carcinomatosis-301441158.html
https://www.prnewswire.com/Sitemap_Index_Jun_2021.xml.gz
https://www.prnewswire.com/Sitemap_Index_Apr_2021.xml.gz
https://www.prnewswire.com/Sitemap_Index_Mar_2021.xml.gz
https://www.prnewswire.com/news-releases/5g-is-on-the-fast-track-spurred-by-covid-19-301110685.html
https://www.prnewswire.com/Sitemap_Index_Jun_2020.xml.gz
https://www.prnewswire.com/news-releases/2020-outlook-into-the-global-omega-3-polyunsaturated-fatty-acids-market-301026878.html
https://www.prnewswire.com/Sitemap_Index_Feb_2020.xml.gz
https://www.prnewswire.com/Sitemap_Index_Sep_2012.xml.gz
https://www.prnewswire.com/news-releases/global-airway-management-devices-market-report-2023-2033-rising-demand-for-advanced-airway-management-devices-driven-by-surgical-surges-and-chronic-illnesses-302029630.html
https://www.prnewswire.com/news-releases/global-educational-furniture-market-analysis-report-2033-a-6-19-billion-industry-by-2028-fueled-by-evolving-classroom-dynamics-enrollment-surge-and-government-initiatives-302029798.html
https://www.prnewswire.com/news-releases/united-states-mobile-medical-imaging-service-market-report-2024-2029-long-term-care-centers-and-palliative-care-drive-demand-302013394.html
https://www.prnewswire.com/news-releases/global-feed-phytogenics-industry-report-2022-and-2023-2030-market-benefits-as-sustainability-gains-prominence-in-animal-feed-industry-302011728.html
https://www.prnewswire.com/news-releases/netherlands-buy-now-pay-later-business-report-2023-a-17-4-billion-market-by-2028-from-8-billion-in-2022-featuring-afterpay-klarna-billink-and-paypal-301997051.html
https://www.prnewswire.com/news-releases/global-nuclear-fusion-technologies-market-expected-to-skyrocket-to-6-8-billion-by-2040--driven-by-technological-advancements-and-private-investment-301983145.html
https://www.rebiotix.com/stool-donor-program/
https://www.prnewswire.com/news-releases/online-distribution-surges-global-superfood-powders-market-adapts-to-changing-consumer-habits-301934811.html
https://www.prnewswire.com/news-releases/global-aromatherapy-diffuser-market-report-2023-increasing-popularity-of-aromatherapy-bolsters-growth-301856881.html
https://www.prnewswire.com/news-releases/unpack-24-tendencias-de-viaje-en-expedia-hoteles-com-y-vrbo-855329728.html
https://adisotx.com/leadership-team/
https://www.smmttx.com/app/uploads/2020/07/20F-2019.pdf
https://www.smmttx.com/app/uploads/2019/12/201912_Fundraise-and-GM-Circular-FINAL.pdf
https://www.smmttx.com/app/uploads/2019/06/2019_Summit-Therapeutics-20-F.pdf
https://www.smmttx.com/app/uploads/2018/06/2016-20F-FINAL.pdf
https://www.smmttx.com/app/uploads/2018/06/Summit-Therapeutics-20F-2018-FINAL-DOCUMENT-FILED-for-website-with-links-and-exhibits.pdf
https://www.smmttx.com/app/uploads/2018/06/2016_RNS_20-ASM-Microbe-Presentation-Alert-FINAL.pdf
https://www.smmttx.com/app/uploads/2018/06/2016_RNS_16-CoM-Patent-Grant-for-Ridinilazole-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_2016_RNS_13-ECCMID-Data-FINAL.pdf
https://www.smmttx.com/app/uploads/2018/06/2016_RNS_07-CoDIFy-Microbiome-Topline-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_2016_RNS_01-Ridinilazole-EU-Patent-grant-FINAL.pdf
https://www.prnewswire.com/news-releases/ferring-pharmaceuticals-1st-in-class-cdiff-treatment-rebyota-experiences-a-positive-early-launch-ahead-of-potential-competition-according-to-spherix-global-insights-301775185.html
https://www.prnewswire.com/news-releases/microbiome-therapeutics-market-to-reach-973-63-million-by-2030-at-a-31-24-cagr-301634544.html
https://www.prnewswire.com/news-releases/overt-hepatic-encephalopathy-market-is-booming-worldwide-the-market-size-is-supposed-to-increase-at-a-decent-compound-annual-growth-rate-cagr-during-the-study-period-20192032-evaluates-delveinsight-301517636.html
https://www.prnewswire.com/news-releases/could-microbiome-based-therapeutics-fill-the-unmet-need-in-recurrent-clostridioides-difficile-c-diff-treatment-spherix-investigates-301508372.html
https://www.prnewswire.com/news-releases/hepatic-encephalopathy-drugs-in-development-2022---therapeutics-development--assessment-companies-involved-drug-profiles-product-development-milestones-featured-news--press-releases-301503029.html
https://www.prnewswire.com/news-releases/hepatic-encephalopathy-market-to-procure-from-ageing-population-and-increased-rd-investments-anticipated-steady-growth-boost-at-a-cagr-of-5-31-during-the-study-period-20182030--evaluates-delveinsight-301409947.html
https://www.prnewswire.com/news-releases/microbiome-therapeutics-innovation-group-highlights-member-company-activity-at-idweek-2019-300928074.html
https://www.mgb-biopharma.com/wp-content/uploads/BWT03282019.pdf
https://www.prnewswire.com/news-releases/global-microbiome-therapeutics--diagnostics-market-2018-2023---human-therapeutic-and-diagnostic-pipeline-analysis-300713586.html
https://verbbiotics.com/op-ed-whats-new-in-gut-health-and-sports-nutrition/
https://verbbiotics.com/media/
https://www.prnewswire.com/news-releases/gut-health-survey-highlights-need-to-educate-consumers-on-the-gut-microbiome-for-overall-health-301980235.html
https://verbbiotics.com/privacy-policy/
https://verbbiotics.com/impact-of-gut-health-in-the-us/
https://verbbiotics.com/terms-of-use/
https://verbbiotics.com/op-ed-can-postbiotics-be-the-answer-to-athletes-gi-distress/
https://verbbiotics.com/approach/
https://verbbiotics.com/solutions/
https://verbbiotics.com/
https://www.paratekpharma.com/medical-affairs/publications-and-presentations?c79ade26_page=3
https://www.paratekpharma.com/careers
https://www.paratekpharma.com/investor-relations/press-release?i=129131
https://www.paratekpharma.com/investor-relations/press-release?i=127340
https://www.paratekpharma.com/
https://www.paratekpharma.com/conference-years/2023-2024
https://www.paratekpharma.com/about
https://www.paratekpharma.com/medical-affairs/publications-and-presentations?c79ade26_page=7
https://www.prnewswire.com/news-releases/novo-holdings-advances-antimicrobial-resistance-strategy-with-acquisition-of-paratek-pharmaceuticals-301934920.html
https://www.paratekpharma.com/investor-relations/press-release?i=126945
https://www.mgb-biopharma.com/useful-links/
https://www.mgb-biopharma.com/scientific-advisory-board/
https://www.mgb-biopharma.com/mgb-biopharma-successful-end-of-phase-2-meeting-with-fda-for-mgb-bp-3-a-potential-new-gold-standard-first-line-treatment-for-clostridioides-difficile-infection-cdi/
https://www.prnewswire.com/news-releases/mgb-biopharma---successful-end-of-phase-2-meeting-with-fda-for-mgb-bp-3-a-potential-new-gold-standard-first-line-treatment-for-clostridioides-difficile-infection-cdi-301215669.html
https://www.prnewswire.com/news-releases/mgb-biopharma-announces-successful-outcome-from-phase-ii-clinical-study-with-mgb-bp-3--a-potential-new-gold-standard-first-line-treatment-for-clostridium-difficile-infection-cdi-301061497.html
https://www.mgb-biopharma.com/mgb-biopharma-presents-at-invetival-showcase-2019/
https://www.mgb-biopharma.com/mgb-biopharma-to-attend-upcoming-bioeurope-meeting-in-hamburg-on-11-to-13-nov-2019/
https://www.mgb-biopharma.com/mgb-biopharma-announces-promising-phase-iia-clinical-trial-update-for-mgb-bp-3/
https://valneva.com/investors/stock-price/?lang=de
https://valneva.com/?lang=fr
https://valneva.com/press-release/valneva-vaccinates-first-participant-in-pediatric-trial-of-single-shot-chikungunya-vaccine/
https://valneva.com/press-release/valneva-vaccinates-first-participant-in-pediatric-trial-of-single-shot-chikungunya-vaccine/?lang=de
https://valneva.com/unveiling-the-lesser-known-impact-of-climate-change-the-rise-of-mosquito-borne-diseases/
https://valneva.com/events/42nd-annual-j-p-morgan-healthcare-conference/
https://valneva.com/about-us/our-team/?lang=de
https://valneva.com/press-release/valneva-to-conduct-investor-meetings-during-the-j-p-morgan-healthcare-conference-and-oddo-bhf-forum-2/?lang=de
https://valneva.com/?lang=de
https://valneva.com/press-release/valneva-to-conduct-investor-meetings-during-the-j-p-morgan-healthcare-conference-and-oddo-bhf-forum-2/
https://crestonepharma.com/knowledge-portal/
https://crestonepharma.com/flagella-classifications-and-how-it-benefits-bacteria/
https://crestonepharma.com/category/events/
https://crestonepharma.com/an-overview-of-nontuberculous-mycobacteria-symptoms/
https://crestonepharma.com/peptidoglycan-what-exactly-is-it/
https://crestonepharma.com/why-are-gram-negative-bacteria-harder-to-kill-with-antibiotics/
https://crestonepharma.com/why-it-is-important-to-always-finish-your-antibiotics/
https://crestonepharma.com/presentation-at-the-2022-national-c-diff-advocacy-summit/
https://crestonepharma.com/c-diff-infection-symptoms-an-overview/
https://openbiome.org/feature/openbiome-recognized-as-a-global-health-leader-by-gbc-health/
https://openbiome.org/feature/fda-approval-of-microbiome-based-therapy-expands-access-for-patients-openbiome-continues-distribution-of-fecal-microbiota-transplantation-fmt/
https://openbiome.org/feature/openbiome-welcomes-joanne-kamens-phd-to-board-of-directors/
https://openbiome.org/feature/openbiome-announces-additions-and-transitions-to-board-of-directors/
https://openbiome.org/wp-content/uploads/Order-Form_August-2023.pdf
https://openbiome.org/filling-gaps-in-microbiome-health-research/
https://openbiome.org/wp-content/uploads/MTP-101LFClinicians-Checklist_July2023-.pdf
https://ondinebio.com/investors/aim-rule-26/
https://ondinebio.com/successful-c4-91-raise-supports-ongoing-commercialisation/
https://ondinebio.com/investors/regulatory-news/
https://ondinebio.com/author/amandavanepercy-com/
https://ondinebio.com/steriwave-featured-daily-mail/
https://ondinebio.com/tag/infection-control/
https://ondinebio.com/photodisinfection-recommended-as-standard-of-care/
https://ondinebio.com/category/amr/
https://ondinebio.com/steriwave-named-as-spie-prism-awards-finalist/
https://www.biomicamed.com/pipeline/
https://www.biomicamed.com/
https://www.exeliombio.com/science/fprau-in-immuno-oncology
https://www.exeliombio.com/science/f-prau
https://www.exeliombio.com/
https://www.smmttx.com/press-releases/
https://www.smmttx.com/our-company/business-development/c-difficile-infection/
https://www.smmttx.com/app/uploads/2018/06/ID-Week-2017-CoDIFy2-FINAL.pdf
https://www.prnewswire.com/news-releases/clostridium-difficile-infection-market-to-show-immense-growth-at-a-cagr-of-12-5-during-the-study-period-20192032--delveinsight-301702515.html
https://www.prnewswire.com/news-releases/akeso-inc-announces-collaboration-and-license-agreement-for-up-to-us5-billion-with-summit-therapeutics-to-accelerate-global-development-and-commercialization-of-its-breakthrough-bispecific-antibody-ivonescimab-pd-1vegf-301695787.html
https://www.prnewswire.com/news-releases/microbiome-clinical-trial-pipeline-space-brims-with-novel-emerging-therapies-with-130-key-players-working-in-the-domain--delveinsight-301672552.html
https://www.smmttx.com/app/uploads/2022/10/2022_PR_1020_ID-Week-2022-Results-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/08/2022_PR_0811_Q2-2022-Financial-Results-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/08/2022_PR_0809_Rights-Offering-2022-Completion-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/08/2022_PR_0802_Rights-Offering-2022-Update-_-FINAL.pdf
https://adisotx.com/
https://www.prnewswire.com/Sitemap_Index_Nov_2018.xml.gz
https://www.prnewswire.com/news-releases/2023-microbiome-market-trends-report-2023-market-is-successfully-commercializing-seres-therapeutics-ser-109-and-rebiotixs-rbx-2660-for-recurrent-clostridium-difficile-infection-302029616.html
https://www.prnewswire.com/news-releases/global-serious-games-market-surges-to-11-17-billion-in-2023--fueled-by-integration-of-emerging-technologies-and-growing-demand-for-learning-solutions-301897783.html
https://www.prnewswire.com/news-releases/alltrna-expands-leadership-team-with-appointments-of-chief-scientific-officer-and-chief-technology-officer-301900137.html
https://www.paratekpharma.com/Serio-ASM-Microbe-2023-OMC-NZW-Rabbit-Anthrax-Poster
https://valneva.com/investors/stock-price/?lang=fr
https://valneva.com/about-us/our-team/
https://openbiome.org/2022-annual-report-draft2/
https://openbiome.org/white-paper-patient-evaluation/
https://openbiome.org/about-us/story/
https://openbiome.org/feature/openbiome-supports-fda-committees-endorsement-of-rbx2660-and-affirms-continued-access-to-fecal-microbiota-transplantation/
https://openbiome.org/feature/openbiome-announces-new-collaboration-with-the-university-of-minnesota-to-treat-patients-with-recurrent-c-difficile-infections/
https://ondinebio.com/about/
https://ondinebio.com/tag/press-release/
https://www.acurxpharma.com/news-media/press-releases/detail/70/acurx-announces-positive-comparative-microbiology-and
https://www.prnewswire.com/news-releases/acurx-announces-positive-comparative-microbiology-and-microbiome-data-for-ibezapolstat-from-phase-2b-clinical-trial-in-cdi-patients-302036789.html
https://www.acurxpharma.com/news-media/press-releases?gclid=EAIaIQobChMI8s73qL_N_QIVEOd3Ch3RjQqpEAMYASABEgJ3rvD_BwE
https://www.prnewswire.com/news-releases/optage-and-nanolock-to-enable-nationwide-iot-security-in-japan-301126682.html
https://www.prnewswire.com/news-releases/microbiome-manufacturing-market-size-and-share-to-surpass-187-million-by-2035--roots-analysis-302034675.html
https://verbbiotics.com/solutions/keystone-postbiotic/
https://www.paratekpharma.com/investor-relations/press-release?i=130169
https://www.paratekpharma.com/medical-affairs/publications-and-presentations?c79ade26_page=4
https://www.paratekpharma.com/investor-relations/press-release?i=121405
https://valneva.com/wp-content/uploads/2024/01/Valneva_Company-Presentation_January_2024.pdf
https://ondinebio.com/jp-errico-appointed-chief-financial-officer/
https://ondinebio.com/about/leadership-team/
https://ondinebio.com/successful-c4-91m-raise-supports-ongoing-commercialisation/
https://ondinebio.com/tag/2023/
https://www.acurxpharma.com/news-media/press-releases/detail/69/acurx-to-present-at-the-42nd-annual-j-p-morgan-healthcare
https://www.acurxpharma.com/news-media/press-releases/detail/64/acurx-announces-ibezapolstat-scientific-posters-and
https://www.acurxpharma.com/news-media/press-releases/detail/63/acurx-pharmaceuticals-announces-successful-completion-and
https://www.acurxpharma.com/news-media/press-releases/detail/62/acurx-announces-presentation-and-update-of-its-pol-iiic-rd
https://www.acurxpharma.com/news-media/press-releases/detail/61/acurx-pharmaceuticals-to-present-at-the-h-c-wainwright
https://microbiotica.com/from-laboratory-to-the-clinic-medicine-after-covid/
https://microbiotica.com/anaerobe-2022/
https://microbiotica.com/microbiome-connect-eu/
https://microbiotica.com/on-helix-bio-innovation-in-prevention/
https://microbiotica.com/milner-therapeutics-symposium/
https://valneva.com/wp-content/uploads/2021/07/Chikungunya_ECCMID2021.pdf
https://www.rebiotix.com/wp-content/uploads/microbiome-bile-acid-restoration-consistent-across-three-clinical-trials-rbx2660-recurrent-clostridioides-difficile-infection-combined-analysis-abstract.docx
https://www.rebiotix.com/wp-content/uploads/treatment-success-reducing-recurrent-clostridioides-difficile-infection-investigational-live-biotherapeutic-rbx2660-associated-microbiota-restoration-consistent-evidence-phase-3-clinical-trial-poster.pdf
https://www.rebiotix.com/wp-content/uploads/interim-analysis-phase-3-open-label-study-indicates-safety-efficacy-rbx2660-investigational-live-biotherapeutic-real-world-population-patients-recurrent-clostridioides-difficile-infection-poster.pdf
https://www.rebiotix.com/wp-content/uploads/Rebiotix-Stool-Donor-Welcome.pdf
https://www.rebiotix.com/wp-content/uploads/durable-reduction-clostridioides-difficile-infection-recurrence-microbiome-restoration-after-treatment-rbx2660-results-open-label-phase-2-clinical-trial.pdf
https://www.rebiotix.com/wp-content/uploads/improvement-microbiome-health-index-patients-recurrent-clostridiodes-difficile-infections-rbx2660-treatment-reduction-antimicrobial-resistance-genes-poster.pdf
https://www.rebiotix.com/wp-content/uploads/changing-the-microbiome-patients-successful-outcome-following-microbiota-based-rbx2660-treatment-healthy-subjects-profile-abstract.pdf
https://www.serestherapeutics.com/our-products/VOWST_PI.pdf
https://www.serestherapeutics.com/patients-and-physicians/Expanded_Access.pdf
https://www.serestherapeutics.com/our-products/
https://www.serestherapeutics.com/about-us/
https://www.serestherapeutics.com/patients-and-physicians/
https://www.serestherapeutics.com/wp-content/uploads/2021/10/Hohmann-E-HRQoL-IDWeek-2021-Oral-LB19.pdf
https://www.serestherapeutics.com/wp-content/uploads/2021/10/Louie-T-Time-to-Recurrence-IDWeek-2021-Poster-639.pdf
https://www.serestherapeutics.com/wp-content/uploads/2021/10/Cohen-SH-Risk-Factors-IDWeek-2021-Poster-634.pdf
https://www.serestherapeutics.com/wp-content/uploads/2021/10/McChalicher-C-Inactivation-ID-Week-2021-Poster-1035.pdf
https://www.smmttx.com/app/uploads/2022/07/2022_PR_0726_Appointment-of-Maky-as-Co-CEO-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/07/2022_PR_0714_Ridinilazole-Update-_-FINAL-1.pdf
https://www.smmttx.com/app/uploads/2022/06/2022_PR_0603_Annual-Shareholders-Meeting-_-FINAL.pdf
https://www.paratekpharma.com/investor-relations/press-release?i=126694
https://www.paratekpharma.com/investor-relations/press-release?i=121391
https://www.paratekpharma.com/investor-relations/press-release?i=119851
https://www.paratekpharma.com/investor-relations/press-release?i=119687
https://www.paratekpharma.com/investor-relations/press-release?i=119663
https://www.mgb-biopharma.com/mgb-biopharma-announces-successful-outcome-from-phase-ii-clinical-study-with-mgb-bp-3-a-potential-new-gold-standard-first-line-treatment-for-clostridium-difficile-infection-cdi/
https://www.mgb-biopharma.com/mgb-biopharma-announces-completion-of-funding-round/
https://www.mgb-biopharma.com/bio-europe-2019/
https://crestonepharma.com/company/
https://openbiome.org/microbiome-education/openbiome-courses/
https://openbiome.org/the-global-microbiome-conservancy-gmbc/gmbc-consortium/
https://www.acurxpharma.com/news-media/press-releases/detail/71/acurx-pharmaceuticals-to-present-at-the-microcap
https://verbbiotics.com/probiotic-efficacy-measurement/
https://verbbiotics.com/about/
https://verbbiotics.com/our-team/
https://www.paratekpharma.com/investor-relations/press-release?i=119290
https://www.paratekpharma.com/investor-relations/press-release?i=117353
https://www.paratekpharma.com/investor-relations/press-release?i=116490
https://www.paratekpharma.com/investor-relations/press-release?i=114568
https://www.paratekpharma.com/investor-relations/press-release?i=113442
https://valneva.com/investors/
https://valneva.com/
https://valneva.com/media-kit/?lang=de
https://crestonepharma.com/antibiotic-antimicrobial-resistance-how-does-it-happen-what-are-the-consequences/
https://ondinebio.com/ondine-unveils-new-research-at-spie-photonics-west/
https://ondinebio.com/investors/corporate-governance/
https://verbbiotics.com/author/brookeb/
https://verbbiotics.com/op-ed-the-untapped-potential-of-postbiotics-why-clarity-is-key/
https://www.paratekpharma.com/investor-relations/press-release?i=97458
https://www.paratekpharma.com/investor-relations/press-release?i=112186
https://www.paratekpharma.com/investor-relations/press-release?i=109979
https://www.paratekpharma.com/investor-relations/press-release?i=101588
https://www.paratekpharma.com/investor-relations/press-release?i=99988
https://www.paratekpharma.com/investor-relations/press-release?i=95911
https://valneva.com/events/guggenheim-healthcare-talks-6th-annual-biotechnology-conference/
https://valneva.com/press-release/valneva-announces-sale-of-priority-review-voucher-for-103-million/
https://valneva.com/press-release/valneva-announces-sale-of-priority-review-voucher-for-103-million/?lang=de
https://valneva.com/wp-content/uploads/2024/01/Valneva_Company-Presentation_February_2024.pdf
https://ondinebio.com/microbiome-research-supports-use-of-steriwave/
https://www.acurxpharma.com/news-media/press-releases/detail/72/acurx-announces-positive-extended-clinical-cure-data-for
https://www.rebiotix.com/wp-content/uploads/microbiome-profile-patients-successful-response-rbx2660-relative-to-placebo-responders-recurrent-c-diff-abstract.pdf
https://www.serestherapeutics.com/wp-content/uploads/2021/10/Halvorsen-E-SER-155-ID-Week-2021-Oral-130.pdf
https://www.smmttx.com/app/uploads/2022/06/2022_PR_0601_New-Officer-Ankur-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/05/2022_PR_0511_Q1-2022-Financial-Results-_-FINAL.pdf
https://www.paratekpharma.com/investor-relations/press-release?i=99016
https://valneva.com/wp-content/uploads/2024/02/Valneva_Company-Presentation_February_2024.pdf
https://www.smmttx.com/app/uploads/2022/04/ECCMID2022_02458_RDZ_MoA_poster_portrait_final.pdf
https://www.paratekpharma.com/investor-relations/press-release
https://valneva.com/press-release/valneva-reports-full-year-2023-revenue-and-cash-provides-first-2024-guidance/?lang=de
https://valneva.com/press-release/valneva-reports-full-year-2023-revenue-and-cash-provides-first-2024-guidance/
https://openbiome.org/careers/
https://openbiome.org/about-us/team/
https://www.acurxpharma.com/news-media/press-releases/detail/60/acurx-pharmaceuticals-inc-reports-second-quarter-2023
https://valneva.com/events/world-vaccine-congress-washington-2024/
https://valneva.com/wp-content/uploads/2024/02/Valneva_Company-Presentation_February_2024a-v2.pdf
https://valneva.com/events/guggenheim-healthcare-talks-6th-annual-biotechnology-conference/?lang=de
https://crestonepharma.com/what-is-post-convalescent-c-difficile/
https://openbiome.org/publication/donor-screening-for-fecal-microbiota-transplantation-2/
https://openbiome.org/feature/openbiome-ships-70000th-investigational-fmt-to-treat-c-difficile/
https://openbiome.org/fmt-efficacy/
https://www.acurxpharma.com/news-media/press-releases/detail/73/acurx-announces-fda-has-granted-an-end-of-phase-2-meeting
https://www.smmttx.com/app/uploads/2022/01/Summit-8pg-brochure-Digital_V1_01102022.pdf
https://www.smmttx.com/app/uploads/2021/11/1052_IDWeek2021-Summit-therapeutics-ridinilazole-MoA_Final.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_27-06-2018_RNS_30-PhaseOut-Full-Results-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_2021_PR_0701_Upcoming-Conference-ECCMID-_-FINAL.pdf
https://verbbiotics.com/solutions/gaba-probiotic/
https://www.mgb-biopharma.com/asm-microbe-2019/
https://valneva.com/events/td-cowen-44th-annual-health-care-conference/
https://valneva.com/press-release/valneva-to-present-at-upcoming-td-cowen-and-van-lanschot-kempen-healthcare-investor-conferences/?lang=de
https://valneva.com/press-release/valneva-to-present-at-upcoming-td-cowen-and-van-lanschot-kempen-healthcare-investor-conferences/
https://valneva.com/investors/stock-price/
https://valneva.com/press-release/u-s-cdc-advisory-committee-acip-recommends-use-of-valnevas-single-dose-chikungunya-vaccine-ixchiq/
https://valneva.com/press-release/u-s-cdc-advisory-committee-acip-recommends-use-of-valnevas-single-dose-chikungunya-vaccine-ixchiq/?lang=de
https://valneva.com/media/press-releases/?lang=fr
https://openbiome.org/
https://openbiome.org/the-global-microbiome-conservancy-gmbc/
https://www.acurxpharma.com/news-media/press-releases/detail/74/acurx-pharmaceuticals-inc-to-discuss-fourth-quarter-and
https://www.rebiotix.com/wp-content/uploads/rbx2660-safe-superior-to-antibiotic-treated-controls-preventing-recurrent-clostridium-difficile-abstract.pdf
https://www.smmttx.com/app/uploads/2022/06/2022_PR_0602_Annual-Shareholders-Meeting-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/06/2021_PR_0603_Annual-Shareholders-Meeting-_-FINAL.pdf
https://verbbiotics.com/author/celestia/
https://valneva.com/press-release/valneva-to-present-at-upcoming-td-cowen-and-van-lanschot-kempen-healthcare-investor-conferences/?lang=fr
https://valneva.com/press-release/u-s-cdc-advisory-committee-acip-recommends-use-of-valnevas-single-dose-chikungunya-vaccine-ixchiq/?lang=fr
https://crestonepharma.com/
https://ondinebio.com/ondine-starts-first-uk-health-economics-study/
